189 related articles for article (PubMed ID: 34420870)
1. Utility of stromal tumor infiltrating lymphocyte scoring (sTILs) for risk stratification of patients with muscle-invasive urothelial bladder cancer after radical cystectomy.
Sikic D; Weyerer V; Geppert CI; Bertz S; Lange F; Taubert H; Wach S; Schmitz-Draeger BJ; Wullich B; Hartmann A; Eckstein M
Urol Oncol; 2022 Feb; 40(2):63.e19-63.e26. PubMed ID: 34420870
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy.
Eckstein M; Strissel P; Strick R; Weyerer V; Wirtz R; Pfannstiel C; Wullweber A; Lange F; Erben P; Stoehr R; Bertz S; Geppert CI; Fuhrich N; Taubert H; Wach S; Breyer J; Otto W; Burger M; Bolenz C; Keck B; Wullich B; Hartmann A; Sikic D;
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448798
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating lymphocytes predict survival in ≥ pT2 urothelial bladder cancer.
Ledderose S; Rodler S; Eismann L; Ledderose G; Ledderose C
Pathol Res Pract; 2022 Sep; 237():154037. PubMed ID: 35908386
[TBL] [Abstract][Full Text] [Related]
4. Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer.
Ottley EC; Pell R; Brazier B; Hollidge J; Kartsonaki C; Browning L; O'Neill E; Kiltie AE
J Pathol Clin Res; 2020 Oct; 6(4):238-251. PubMed ID: 32374509
[TBL] [Abstract][Full Text] [Related]
5. Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy.
Taubert H; Eckstein M; Epple E; Jung R; Weigelt K; Lieb V; Sikic D; Stöhr R; Geppert C; Weyerer V; Bertz S; Kehlen A; Hartmann A; Wullich B; Wach S
Cells; 2021 Jan; 10(1):. PubMed ID: 33467469
[TBL] [Abstract][Full Text] [Related]
6. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
7. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
8. Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes.
Eckstein M; Matek C; Wagner P; Erber R; Büttner-Herold M; Wild PJ; Taubert H; Wach S; Sikic D; Wullich B; Geppert CI; Compérat EM; Lopez-Beltran A; Montironi R; Cheng L; van der Kwast T; Colecchia M; van Rhijn BWG; Amin MB; Netto GJ; Lehmann J; Stöckle M; Junker K; Hartmann A; Bertz S
Eur Urol Oncol; 2024 Feb; 7(1):128-138. PubMed ID: 37562993
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy.
Murakami Y; Matsumoto K; Shimizu Y; Ikeda M; Amano N; Shimura S; Ishii D; Sato Y; Iwamura M
Urol Oncol; 2021 Mar; 39(3):195.e15-195.e23. PubMed ID: 33071109
[TBL] [Abstract][Full Text] [Related]
10. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.
Ma B; Li H; Zhang C; Yang K; Qiao B; Zhang Z; Xu Y
Eur J Surg Oncol; 2013 Oct; 39(10):1150-6. PubMed ID: 23721764
[TBL] [Abstract][Full Text] [Related]
11. The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes.
Pfannstiel C; Strissel PL; Chiappinelli KB; Sikic D; Wach S; Wirtz RM; Wullweber A; Taubert H; Breyer J; Otto W; Worst T; Burger M; Wullich B; Bolenz C; Fuhrich N; Geppert CI; Weyerer V; Stoehr R; Bertz S; Keck B; Erlmeier F; Erben P; Hartmann A; Strick R; Eckstein M; ; ; ;
Cancer Immunol Res; 2019 Jun; 7(6):923-938. PubMed ID: 30988029
[TBL] [Abstract][Full Text] [Related]
12. Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy.
Yu A; Mansure JJ; Solanki S; Siemens DR; Koti M; Dias ABT; Burnier MM; Brimo F; Kassouf W
PLoS One; 2018; 13(10):e0205746. PubMed ID: 30308033
[TBL] [Abstract][Full Text] [Related]
13. Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy.
Holland BC; Sood A; Delfino K; Dynda DI; Ran S; Freed N; Alanee S
Cancer Immunol Immunother; 2019 Jun; 68(6):991-997. PubMed ID: 30997535
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis.
Koll FJ; Banek S; Kluth L; Köllermann J; Bankov K; Chun FK; Wild PJ; Weigert A; Reis H
J Transl Med; 2023 Feb; 21(1):124. PubMed ID: 36793050
[TBL] [Abstract][Full Text] [Related]
15. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
Bandini M; Briganti A; Plimack ER; Niegisch G; Yu EY; Bamias A; Agarwal N; Sridhar SS; Sternberg CN; Vaishampayan U; Théodore C; Rosenberg JE; Bellmunt J; Galsky MD; Montorsi F; Necchi A
Eur Urol Oncol; 2019 May; 2(3):248-256. PubMed ID: 31200838
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and outcomes of transurethral resection versus radical cystectomy for muscle-infiltrating bladder cancer in the United States: A population-based cohort study.
Zheng Y; Ye Y; Chen J; Wei Z; Liu Z; Yu K; Zhang X
Int J Surg; 2022 Jul; 103():106693. PubMed ID: 35690361
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer.
Nederlof I; De Bortoli D; Bareche Y; Nguyen B; de Maaker M; Hooijer GKJ; Buisseret L; Kok M; Smid M; Van den Eynden GGGM; Brinkman AB; Hudecek J; Koster J; Sotiriou C; Larsimont D; Martens JWM; van de Vijver MJ; Horlings HM; Salgado R; Biganzoli E; Desmedt C
Breast Cancer Res; 2019 Dec; 21(1):151. PubMed ID: 31878981
[TBL] [Abstract][Full Text] [Related]
18. Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands.
Hinsenveld FJ; Boormans JL; van der Poel HG; van der Schoot DKE; Vis AN; Aben KKH; Arends TJ; Ausems PJ; Baselmans D; Berger C; Berrens A; Bickerstaffe H; Bos SD; Braam M; Buddingh KT; Claus S; Dekker K; van Doeveren T; Einerhand S; Fossion L; van Gennep EJ; van Ginkel N; Palacios G; Hermans T; Hobijn MM; van Huystee SH; Jaspers-Valentijn M; Klaver OS; Koldewijn EL; Korsten L; Lenting A; Lentjes KJ; Luiting HB; van der Meer S; Nieuwenhuijzen JA; Noordzij MA; Nooter RI; Notenboom C; Oomen R; van Roermund J; de Rooij J; Roshani H; Schrier BP; van der Slot MA; Somford DM; Stelwagen PJ; Stroux A; van der West A; Wijsman BP; Windt W; van Zanten P; van Beek SC;
Urol Oncol; 2022 Feb; 40(2):60.e1-60.e9. PubMed ID: 34303597
[TBL] [Abstract][Full Text] [Related]
19. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy.
Moschini M; Sharma V; Dell'oglio P; Cucchiara V; Gandaglia G; Cantiello F; Zattoni F; Pellucchi F; Briganti A; Damiano R; Montorsi F; Salonia A; Colombo R
BJU Int; 2016 Apr; 117(4):604-10. PubMed ID: 25851271
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.
Black AJ; Zargar H; Zargar-Shoshtari K; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Griffin J; Montgomery JS; Vasdev N; Yu EY; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Stephenson AJ; Shah JB; van Rhijn BW; Spiess PE; Daneshmand S; Sridhar SS; Black PC
Urol Oncol; 2020 Jan; 38(1):3.e17-3.e27. PubMed ID: 31676278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
